Publications by authors named "S A Grishin"
The electrochemically mediated cyanation/annulation process with in situ cyanide ion generation from NH4SCN and multi-step oxidative construction of CN-functionalized heterocycles from easily available α-amino esters and pyridine-2-carbaldehydes has been discovered. Depending on the nature of the α-amino ester, 1-cyano-imidazo[1,5-a]pyridine-3-carboxylates, 3-alkyl- and 3-aryl-imidazo[1,5-a]pyridines-1-carbonitriles, and the first reported 4-oxo-4H-pyrido[1,2-a]pyrazine-1-carbonitriles were obtained. The electrosynthesis is carried out in an undivided electrochemical cell under constant current conditions.
View Article and Find Full Text PDFIn a randomized double-blinded clinical trial of patients with ST segment elevation myocardial infarction (STEMI), goflikicept, an interleukin-1 blocker, significantly reduced systemic inflammation, measured as the area under the curve (AUC) for high-sensitivity C reactive protein at 14 days. We report secondary analyses of biomarkers at 28 days, and cardiac function and clinical end points at 1 year. Patients received a single administration of goflikicept 80 mg (n = 34), goflikicept 160 mg (n = 34), or placebo (n = 34).
View Article and Find Full Text PDFArticle Synopsis
- A clinical trial evaluated the effects of goflikicept, an IL-1 blocker, in patients with STEMI and found it significantly reduced systemic inflammation measured by hsCRP levels at both 14 and 28 days.
- Two doses of goflikicept (80 mg and 160 mg) showed similar effectiveness in reducing hsCRP without significant differences in cardiac biomarkers or clinical outcomes like death and hospitalization compared to a placebo.
- The study concluded that goflikicept is well tolerated and effectively reduces inflammation but highlighted the need for further research to see if this reduction leads to actual clinical benefits for STEMI patients.
Aims: In patients with rheumatoid arthritis (RA), interleukin (IL)-6 affects the activity of cytochrome P450 (CYP) enzymes. Treatment with anti-IL-6 therapy can reverse the IL-6-mediated downregulation of CYP enzymes, resulting in changes in plasma levels of CYP substrates. The primary objective of this study was to evaluate the impact of the IL-6 inhibitor olokizumab on the pharmacokinetics of CYP probe substrates in subjects with active RA.
View Article and Find Full Text PDF